Gibson Dunn & Crutcher advised Arrowhead Pharmaceuticals, Inc. on the transaction, and Ropes & Gray advised Sarepta Therapeutics.Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced a global licensing…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
